Caris Expands Lab Facilities and Offerings

Caris Life Sciences® focuses on fulfilling the promise of personalized medicine through combining the company’s advanced laboratory testing, including tumor profiling and innovative blood-based cancer diagnostics, with the utilization of artificial intelligence algorithms to make predictions of benefit from standard treatments. With the recent launch of several new products, including MI GPSai™, MI FOLFOXai™ and Whole Exome Sequencing, and the significant growth of the laboratory footprint in Phoenix, Caris continues to expand its capabilities, giving even more patients with cancer access to personalized medicine.

Since acquiring Phoenix-based Molecular Profiling Institute in 2007 with only 50 employees at the time, Caris now has over 700 employees based locally including pathologists, lab technicians, lab supervisors, molecular technologists as well as QA/QC, regulatory and other support functions. The overarching concept of Caris Molecular Intelligence® has enabled Caris to advance precision medicine through comprehensive tumor profiling of DNA, RNA and protein biomarkers, revealing the highest quality molecular blueprints for selection of the most appropriate cancer therapeutic regimens.

Caris has three clinical lab facilities in the United States—all CLIA-, CAP-certified and ISO-accredited upon completion—covering approximately 225,000 sq ft of space in the Phoenix/Tempe area. Almost half of the space is dedicated to the molecular laboratory and support facilities for processing patient specimens and developing new tests. Caris also finished construction in late 2020 at their newest lab facility in the Papago Gateway Building in Tempe, which houses its R&D, Bioinformatics and Cognitive Computing teams along with additional support functions.

An additional 35,000 square feet of lab space in Phoenix is currently under construction and is scheduled to open sometime this year. The new lab will be designated as the company’s blood-based profiling operations where Caris continues to expand its molecular testing technologies and AI capabilities with the addition of a novel blood-based liquid profiling approach and molecular profiling for hematologic malignancies, among others.

Caris provides the following robust genomic and proteomic testing capabilities across a variety of specimen types and high-throughput technologies:

Technologies (abbreviated list):

  • Flow Cytometry

  • Fragment Analysis

  • Immunohistochemistry (IHC)

  • in situ Hybridization (ISH)

  • Laser Capture Microdissection

  • Mass Spectrometry

  • Next-Generation Sequencing

  • DNA and RNA

  • Somatic and Germline

  • Point Mutations, Indels, Fusions and Copy Number Variations

  • Whole Exome and Whole Transcriptome

  • Sanger Sequencing

  • Pyro Sequencing

  • Quantitative Polymerase Chain Reaction (qPCR)

  • RT-PCR

Annotated Biorepository Access:

  • Thousands of molecularly annotated samples with millions of slides

  • Climate controlled/monitored storage environments, including temperatures of 4°C, -20°C and -80°C

  • Processing and analysis

  • Reporting